“A Multi-Center, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Pharmacokinetics, and Explore the Efficacy of Sofpironium Bromide Gel, 15% Applied Topically to Children/Adolescents, 9-16 Years, with Primary Axillary Hyperhidrosis” (2020) SKIN The Journal of Cutaneous Medicine, 4(6), p. s116. doi:10.25251/skin.4.supp.116.